Status:
ACTIVE_NOT_RECRUITING
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of TVAX-008 Injection in Chronic Hepatitis B Patients
Lead Sponsor:
Grand Theravac Life Sciences (Nanjing) Co., Ltd.
Collaborating Sponsors:
Nanfang Hospital, Southern Medical University
Sichuan Provincial People's Hospital
Conditions:
HBV Infection
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The objective of this study was to evaluate the efficacy and safety of TVAX- 008 injection in a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II clinical trial in sub...
Eligibility Criteria
Inclusion
- \- aged 18\~65 ； Serum HBsAg positive ≥ 6 months； HBeAg negative；
Exclusion
- Treatment with interferon or pegylated interferon within 12 weeks prior to first use of investigational product; or planned treatment with interferon or pegylated interferon during the trial;
Key Trial Info
Start Date :
January 22 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT07179653
Start Date
January 22 2025
End Date
December 1 2026
Last Update
September 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
NanFang Hospital
Guangzhou, Guangdong, China, 20000